GLP-1 Medicine: page 16

Articles 901 to 960 of 2,305.

Can I Take L-Theanine With Zepbound (Tirzepatide)?

A thorough clinical review of L-theanine and Zepbound (tirzepatide) interactions, covering pharmacokinetics, pharmacodynamics, dosing, and monitoring guidance from the HealthRX.com medical team.

Can I Take Lion's Mane with Zepbound (Tirzepatide)?

A guide covering the known interactions, safety data, and monitoring considerations for combining lion's mane mushroom with Zepbound (tirzepatide) for weight management.

Ozempic Re-Titration After Stopping: How to Safely Restart Semaglutide

Stopped Ozempic and need to restart? This clinical guide covers the FDA-approved re-titration schedule for semaglutide 0.5 to 2.0 mg, what the evidence says about restarting after a gap, and how to minimize side effects.

Wegovy Re-Titration After Stopping: How to Restart Semaglutide Safely

Learn exactly how to re-titrate Wegovy (semaglutide 2.4 mg) after a dose interruption, including FDA-label guidance, clinical trial data, and restart protocols.

Wegovy Geriatric (65+) Dosing: What Older Adults and Their Clinicians Need to Know

A guide to Wegovy (semaglutide 2.4 mg) dosing in adults aged 65 and older, covering titration schedules, renal and hepatic considerations, fall risk, polypharmacy, and deprescribing thresholds.

Wegovy History & Development: From GLP-1 Discovery to FDA Approval

A clinician-level history of Wegovy (semaglutide 2.4 mg): the GLP-1 science, Novo Nordisk's development program, STEP trial data, FDA approval timeline, and what the evidence means for chronic weight management.

Wegovy Metabolism and Energy Expenditure: What Semaglutide 2.4 mg Actually Does to Your Metabolic Rate

A clinician-level review of how Wegovy (semaglutide 2.4 mg) affects resting energy expenditure, thermogenesis, fat oxidation, and adaptive thermogenesis, with primary-literature citations and real dose data.

Wegovy Pre-Surgery Hold Window: How Long to Stop Semaglutide Before an Operation

A guide to the Wegovy (semaglutide 2.4 mg) pre-surgery hold window, covering aspiration risk, gastric emptying data, society guidelines, and the dose-restart protocol after surgery.

Wegovy Seasonal Use Considerations: What Patients and Clinicians Need to Know

A clinical deep-dive into how seasonal factors, including heat, holidays, activity shifts, and injection-site changes, affect semaglutide 2.4 mg (Wegovy) therapy, with evidence-based guidance on dose timing, storage, and monitoring adjustments.

Zepbound (Tirzepatide) Pediatric Monitoring: What Clinicians and Parents Need to Know for Children Under 12

A clinician-focused guide to monitoring children under 12 on or being considered for Zepbound (tirzepatide), covering FDA labeling status, growth tracking, metabolic labs, injection safety, and evidence from pediatric GLP-1/GIP trials.

Mounjaro vs Rybelsus: Cost and Access Head-to-Head

A clinical comparison of Mounjaro (tirzepatide) and Rybelsus (oral semaglutide) covering efficacy, cost, insurance access, dosing, and who each drug suits best.

Does Anthem Cover Tirzepatide (Mounjaro)?

A detailed guide to Anthem's tirzepatide (Mounjaro) coverage policies, prior authorization requirements, formulary tiers, appeal strategies, and cost-saving options, prepared by the HealthRX.com Editorial Team.

Wegovy and Finasteride Interaction: What Patients and Clinicians Need to Know

A clinical evidence review of the pharmacokinetic and pharmacodynamic considerations between semaglutide 2.4 mg (Wegovy) and finasteride, including what is established, what is plausible but unproven, and what should be verified before assuming the combination is risk-free.

Mounjaro for Metabolic Syndrome: Evidence, Dosing, and What to Expect

A guide to using tirzepatide (Mounjaro) for metabolic syndrome, covering trial evidence, dosing schedules, and real-world outcomes.

Mounjaro for Childhood Obesity: Is It Approved or Safe?

Mounjaro has no FDA approval and no controlled trials in children under 12. See what the evidence shows and current AAP guideline recommendations instead.

Ozempic for NASH: Off-Label Use, Evidence, and Monitoring Requirements

A guide to using semaglutide (Ozempic 0.5 to 2.0 mg) off-label for NASH, covering the evidence base, GRADE ratings, required monitoring, and what FDA approval means for this indication.

Ozempic Real-World Evidence: What Registries and RWE Studies Actually Show

A deep dive into Ozempic (semaglutide 0.5 to 2.0 mg) real-world evidence from registries, observational cohorts, and post-marketing data. Covers mechanism, effectiveness, safety signals, and how RWE compares to SUSTAIN trial results.

Wegovy Regret, Stopping, and Restarting: What Real Users and Clinical Trials Actually Show

Thinking about stopping Wegovy or restarting after a break? This evidence-based guide covers what regret looks like, why weight returns, and exactly how to restart safely, with data from STEP-1, STEP-4, and real patient forums.

Why Mounjaro (Tirzepatide) Causes Pancreatitis: The Mechanism Explained

A clinical-grade explanation of how tirzepatide's dual GIP/GLP-1 receptor agonism may trigger pancreatitis, what the incidence data show, how to recognize it early, and exactly when to stop the drug.

Medications to Manage Nausea on Ozempic (semaglutide 0.5-2 mg): First-Line and Beyond

A clinical deep-dive into OTC and prescription medications that reduce nausea caused by Ozempic (semaglutide). Covers first-line antiemetics, second-line Rx options, drug interactions to avoid, and dose ranges for real-time management.

Mounjaro Side Effects: Rare but Serious Adverse Events

A clinical deep-dive into tirzepatide's rare but serious adverse events, including pancreatitis, thyroid tumors, gallbladder disease, kidney injury, and more. Backed by SURPASS trial data, FDA labeling, and post-market surveillance.

Wegovy (Semaglutide 2.4 mg) Constipation: Alternatives Without This Side Effect

Wegovy causes constipation in up to 24% of users. Learn why semaglutide slows gut transit, how to manage it, and which GLP-1 alternatives carry a lower constipation burden.

Wegovy and the Kidneys: Renal Protection or Renal Risk?

A physician-level review of semaglutide 2.4 mg (Wegovy) and kidney outcomes, covering the FLOW trial, STEP-1 data, GFR changes, proteinuria, and how to dose-adjust in CKD.

Mounjaro (Tirzepatide) in Adults 65 and Older: A Clinical Transition Guide

Evidence-based guidance on starting, adjusting, and monitoring tirzepatide (Mounjaro) in geriatric patients transitioning from pediatric or general adult care to age-specific protocols, including dose modifications, safety considerations, and clinical outcomes data.

Ozempic in Adults 65 and Older: Off-Label Uses, Dosing Adjustments, and Safety Considerations

A detailed clinical guide to semaglutide 0.5 to 2.0 mg (Ozempic) use in geriatric patients aged 65+, covering off-label indications, age-specific risks, dose titration, and evidence from major trials.

Wegovy for Adolescents (Ages 12 to 17): School and Activity Considerations

How semaglutide 2.4 mg affects school performance, physical activity, and daily routines for adolescents ages 12 to 17, with dosing timelines, side-effect management, and evidence-based guidance for parents and prescribers.

Zepbound Geriatric (65+) Caregiver Administration Guidance

A complete clinical guide for caregivers helping adults aged 65 and older administer Zepbound (tirzepatide) injections safely, including dose preparation, injection technique, storage, side-effect monitoring, and when to call the prescriber.

Mounjaro vs Liraglutide: Switching Between Them Explained

A clinical comparison of tirzepatide (Mounjaro) and liraglutide on weight loss, A1C reduction, dosing, and how to switch between them safely. prepared by the HealthRX.com Editorial Team.

Ozempic vs Trulicity: How to Switch Between Them Safely

A clinical comparison of semaglutide (Ozempic) and dulaglutide (Trulicity) covering efficacy, cardiovascular outcomes, dosing, side effects, and a step-by-step protocol for switching between them.

Ozempic vs Rybelsus: Cost and Access Head-to-Head

A detailed clinical and cost comparison of Ozempic (injectable semaglutide) vs Rybelsus (oral semaglutide) covering efficacy, pricing, insurance access, and who should use which.

Ozempic vs Saxenda Head-to-Head Efficacy: Which GLP-1 Works Better for Weight Loss?

A clinical comparison of semaglutide (Ozempic) vs liraglutide (Saxenda) for weight loss efficacy, dosing, side effects, and cost, with data from SUSTAIN-7, SCALE, and STEP trials.

Wegovy vs Ozempic Side-Effect Profile Head-to-Head

A clinical comparison of Wegovy (semaglutide 2.4 mg) and Ozempic (semaglutide 0.5 to 2.0 mg) side-effect profiles, drawn from STEP-1, SUSTAIN-7, and FDA labeling, with practical guidance on switching and dose titration.

Wegovy vs Rybelsus: Cost and Access Head-to-Head

A clinical comparison of Wegovy (semaglutide 2.4 mg injection) and Rybelsus (oral semaglutide 3 to 14 mg) covering efficacy data, list prices, insurance coverage, and how to choose between them.

Wegovy vs Saxenda Head-to-Head Efficacy: Semaglutide 2.4 mg vs Liraglutide 3 mg

A detailed clinical comparison of Wegovy (semaglutide 2.4 mg) and Saxenda (liraglutide 3 mg) for weight loss, covering trial data, dosing, side effects, cost, and how to choose between them.

Wegovy vs Saxenda Side-Effect Profile Head-to-Head

A clinical comparison of semaglutide 2.4 mg (Wegovy) and liraglutide 3 mg (Saxenda) side-effect profiles, drawn from STEP-1, SCALE, and post-market safety data. prepared by the HealthRX.com Editorial Team.

Zepbound vs Liraglutide: Head-to-Head Efficacy Compared

A detailed clinical comparison of Zepbound (tirzepatide) and liraglutide for weight loss, covering trial data from SURMOUNT-1 and SCALE Obesity, dosing, side effects, and how to choose between them.

Zepbound vs Ozempic Head-to-Head Efficacy: What the Clinical Data Actually Shows

A direct comparison of tirzepatide (Zepbound) and semaglutide (Ozempic) on weight loss, glycemic control, and cardiovascular outcomes, drawing on SURMOUNT-1, SUSTAIN-7, SURPASS trials, and indirect comparison data.

Mounjaro vs Trulicity: Long-Term Durability of Response

A head-to-head clinical comparison of tirzepatide (Mounjaro) and dulaglutide (Trulicity) on long-term blood sugar control, weight loss durability, cardiovascular outcomes, and when switching between the two drugs makes sense.

Mounjaro vs Trulicity: Real-World Evidence Comparison

A head-to-head comparison of tirzepatide (Mounjaro) and dulaglutide (Trulicity) using SURPASS-2, REWIND, and real-world cohort data, covering weight loss, A1C reduction, cardiovascular outcomes, and practical switching guidance.

Mounjaro vs Trulicity: What to Do When One Fails

A clinical comparison of tirzepatide (Mounjaro) and dulaglutide (Trulicity) covering efficacy, failure modes, and step-by-step guidance on when and how to switch between them.

Mounjaro vs Liraglutide: Combining the Two (Rationale + Risk)

A head-to-head clinical comparison of tirzepatide (Mounjaro) and liraglutide, covering efficacy data, switching protocols, combination rationale, and safety risks, prepared by the HealthRX.com Editorial Team.

Mounjaro vs Liraglutide: Long-Term Durability of Response

A head-to-head clinical comparison of tirzepatide (Mounjaro) and liraglutide on long-term weight loss and glycemic durability, drawing on SURPASS-2, SCALE Obesity, SURMOUNT-1, and real-world evidence.

Mounjaro vs Liraglutide: Real-World Evidence Comparison

An evidence-based comparison of tirzepatide (Mounjaro) and liraglutide across clinical trials and real-world data, covering weight loss, blood sugar control, side effects, cost, and when to switch.

Mounjaro vs Liraglutide in Special Populations: A Head-to-Head Comparison

A clinical comparison of tirzepatide (Mounjaro) and liraglutide across special populations including type 2 diabetes, obesity, CKD, cardiovascular disease, and older adults. Includes trial data, dosing guidance, and switching criteria.

Mounjaro vs Liraglutide: What to Do When One Fails

A clinical comparison of tirzepatide (Mounjaro) and liraglutide, covering efficacy data, mechanism differences, and a step-by-step protocol for switching when one agent stops working.

Mounjaro vs Rybelsus: Combining the Two (Rationale + Risk)

A clinical comparison of tirzepatide (Mounjaro) and oral semaglutide (Rybelsus), including why combining them is contraindicated, how each drug works, and how to decide which one to use or whether to switch.

Mounjaro vs Rybelsus: Long-Term Durability of Response

A clinical comparison of tirzepatide (Mounjaro) and oral semaglutide (Rybelsus) for long-term durability of glycemic and weight response, drawing on SURPASS-2, PIONEER-4, and real-world evidence.

Mounjaro vs Rybelsus in Special Populations: A Head-to-Head Clinical Comparison

A detailed head-to-head comparison of tirzepatide (Mounjaro) and oral semaglutide (Rybelsus) across special populations including CKD, heart failure, elderly, and those switching between therapies. prepared by the HealthRX.com Editorial Team.

Mounjaro vs Saxenda: Real-World Evidence Comparison

A head-to-head comparison of tirzepatide (Mounjaro) and liraglutide 3 mg (Saxenda) drawing on clinical trials, real-world registry data, and current guidelines to help patients and clinicians choose the right GLP-1 therapy.

Mounjaro vs Saxenda in Special Populations: Head-to-Head Clinical Comparison

A detailed head-to-head comparison of tirzepatide (Mounjaro) and liraglutide 3 mg (Saxenda) across special populations including type 2 diabetes, cardiovascular disease, renal impairment, older adults, and women with PCOS. Backed by trial data and clinical guidelines.